ANALYSIS OF THE RISK FACTORS FOR THE NEUTROPENIC FEVER IN THE HIGH RISK NHL PATIENTS FOR DEVELOPING FEBRILE NEUTROPENIA WHO RECEIVED 3-WEEKLY CHOP-LIKE CHEMOTHERAPY WITH PRIMARY G-CSF PROPHYLAXIS; PROSPECTIVE MULTICENTER OBSERVATION STUDY: